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Abstract  
Background: Acrylamide was classified as ‘probably carcinogenic to humans (group 2A)’ by the 
International Agency for Research on Cancer. Epithelial ovarian cancer (EOC) is the fourth 
cause of cancer mortality in women. Five epidemiological studies have evaluated the 
association between EOC risk and dietary acrylamide intake assessed using food frequency 
questionnaires, and one nested case-control study evaluated hemoglobin adducts of 
acrylamide (HbAA) and its metabolite glycidamide (HbGA) and EOC risk; the results of these 
studies were inconsistent. 
Methods: A nested case-control study in non-smoking postmenopausal women (334 cases, 
417 controls) was conducted within the European Prospective Investigation into Cancer and 
Nutrition (EPIC) cohort. Unconditional logistic regression models were used to estimate odds 
ratios (OR) and 95% confidence intervals (CI) for the association between HbAA, HbGA, 
HbAA+HbGA, and HbGA/HbAA and EOC and invasive serous EOC risk. 
Results: No overall associations were observed between biomarkers of acrylamide exposure 
analyzed in quintiles and EOC risk; however, positive associations were observed between 
some middle quintiles of HbGA and HbAA+HbGA. Elevated but non-statistically significant ORs 
for serous EOC were observed for HbGA and HbAA+HbGA (ORQ5vsQ1:1.91, 95%CI:0.96-3.81 and 
ORQ5vsQ1:1.90, 95%CI:0.94-3.83, respectively); however, no linear dose-response trends were 
observed. 
Conclusion: This EPIC nested case-control study failed to observe a clear association between 
biomarkers of acrylamide exposure and the risk of EOC or invasive serous EOC. 
Impact: It is unlikely that dietary acrylamide exposure increases ovarian cancer risk; however, 
additional studies with larger sample size should be performed to exclude any possible 
association with EOC risk.  
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Introduction 
In 1994, the International Agency for Research on Cancer (IARC) classified acrylamide as 
‘probably carcinogenic to humans (group 2A)’. Acrylamide is formed in carbohydrate rich foods 
during common cooking procedures such as frying, baking, or roasting, which involve 
temperatures usually higher than 120ºC (1,2).  
Acrylamide is thought to be absorbed in the gastrointestinal tract mainly through passive 
transport, and once it is in the body, is metabolized by at least two pathways: via direct 
conjugation with glutathione for its elimination, or via the Cyp2e1 enzyme system to form  
glycidamide, a DNA-reactive epoxide (3). Both acrylamide and glycidamide can interact with 
hemoglobin to form adducts (HbAA and HbGA, respectively) which are considered relevant 
biomarkers of internal exposure, represent exposure over the life-span of erythrocytes, 
previous ≈4 months (4,5), and have been used in multiple epidemiological and experimental 
studies. In addition to dietary acrylamide intake, tobacco smoking, occupational exposures, 
and environmental tobacco smoke can also influence levels of HbAA and HbGA (6). It has been 
observed that smokers have, on average, three to four times higher levels of hemoglobin 
adducts than non-smokers (7). 
Genotoxic and mutagenic properties have been described in animals after glycidamide 
exposure. Further, several animal studies observed an increase in the incidence of hormone 
and non-hormone related tumors after acrylamide exposure (8).  
Almost 90% of malignant ovarian tumors are epithelial ovarian cancer (EOC), which is the 
seventh most common cancer in women worldwide, and the fourth cause of cancer mortality 
in women (9). The 5-year survival rate ranges between 30-50% depending upon geographic 
region (10). There is epidemiological evidence that both adult attained height and BMI 
increase the risk of developing EOC (11,12), and that tobacco smoking is positively associated 
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with mucinous ovarian cancer (13,14); whereas oral contraceptive (OC) use and full term 
pregnancy are established preventive factors (15).  
Four prospective cohort studies and one case-control study have evaluated the association 
between dietary acrylamide intake (assessed using food frequency questionnaires; FFQ) and 
EOC risk (16–20). A lack of association was reported in an Italian case-control study (20), the 
prospective Swedish Mammography Cohort (SMC) (17), and the EPIC cohort (19). The Nurses’ 
Health Study (NHS) observed a non-statistically significant increased risk only for serous EOC 
tumors (18). Nevertheless, a prospective study within the Netherlands Cohort Study (NLCS) 
observed a statistically significant positive association between high consumption of 
acrylamide and overall EOC risk (16). A nested case-control study was subsequently conducted 
within the NHS and the NHSII (NHS/NHSII) to examine the relation between acrylamide 
exposure measured as hemoglobin adducts and EOC risk (21); however, no evidence for any 
associations for overall EOC or serous EOC risk were observed comparing the highest to the 
lowest tertile of HbAA and HbGA.  
The present nested case-control study was performed in a subgroup of non-smoking 
postmenopausal women from the EPIC cohort with the aim to evaluate the association 
between EOC risk and hemoglobin adducts of acrylamide/glycidamide. Analyses by different 
EOC histological subtype and tumor invasiveness were also performed, as well as stratified 
analyses by known risk and preventive factors in the development of EOC.  
Material and Methods 
Study population and data collection  
The EPIC study is an ongoing multicenter prospective cohort study which comprises 23 
research centers in 10 European countries (France, Italy, Spain, the United Kingdom, The 
Netherlands, Greece, Germany, Sweden, Denmark, and Norway). Norway, Denmark, and a 
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center from Sweden (Malmö) did not participate in the present nested case-control study. All 
EPIC study participants signed an informed consent at recruitment (range: 1992-2000), and the 
study was approved by both the ethical review boards from the IARC, and local ethics 
committees. Details of the study methodology have been previously described (22). 
The EPIC study includes 153,427 men and 367,903 women. At recruitment, participants 
completed country-specific, validated dietary questionnaires (DQs) with the time frame 
referring to the previous year. Information on lifestyle factors (such as tobacco smoking, level 
of education, socioeconomic status, alcohol consumption, and physical activity), 
anthropometric factors, brief occupational history, and medical history were also assessed at 
recruitment. Women also reported baseline information on menstrual and reproductive 
factors (i.e., age at first menstrual period, pregnancy, use of OC, use of hormone replacement 
therapy (HRT), and menopausal status).  
The standardized protocol followed to collect and store blood samples at recruitment has been 
previously published (22). Briefly, almost 80% of the EPIC participants, of which 226,673 were 
women, provided a single blood sample. Most of the samples were stored in liquid nitrogen (-
196ºC) at the IARC bio-bank; however, samples from Sweden (Umeå) were stored in freezers (-
80ºC) at the Medical Biobank of Northern Sweden.  
Identification of epithelial ovarian cancer cases and selection of the study population 
Incident EOC were classified according to the International Classification of Diseases for 
Oncology (ICD-0-3), and included epithelial borderline tumors (C56.9), invasive epithelial 
ovarian (C56.9), fallopian tube (C57.0), and primary peritoneal (C48) cancers. Incident EOC 
were recorded through a combination of methods (health insurance records, cancer and 
pathology registries, and active follow-up), or via population cancer registries. 
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Cases and controls for the present nested case-control study were selected according to the 
methodology described by Peeters et al. (23). To summarize, for each case (participant who 
developed an ovarian, fallopian tube or peritoneal tumor after the date of blood draw and 
before the end of follow-up) two controls free of cancer (with the exception of non-melanoma 
skin cancer) were randomly selected at the time of diagnosis using a density sampling 
protocol. Matching criteria included study center, menopausal status (premenopausal, 
postmenopausal, peri-menopausal), age at recruitment (± 6 months), time of the day of blood 
collection (± 1 h), and fasting status (<3, 3-6, >6 h). For the current study of hemoglobin 
adducts, one control per case was selected. Since acrylamide may disrupt hormonal levels, and 
tobacco smoking is an important source of acrylamide exposure (7,24,25), the present study 
only included women who at baseline reported being postmenopausal and non-smokers (thus, 
individual matching was broken). Postmenopausal women were defined as those who were 
>55 years old, or who reported not having had any menses during the 12 months before 
recruitment. Non-smokers women were defined as those who reported never smoking or 
having given up smoking ≥5 years before recruitment.  
A total of 751 participants (334 EOC cases and 417 controls) were included in the study. EOC 
comprised both borderline (n=2, 1%) and invasive tumors (n=332, 99%). Invasive EOC were 
classified into subtypes: serous (n=191, 58%), endometrioid (n=26, 8%), mucinous (n=18, 5%), 
clear cell (n=12, 3%), not otherwise specified (NOS) which included adenocarcinomas, 
carcinomas, and cystadenocarcinoma (n=79, 24%), and others (n=6, 2%).  
Measurement of acrylamide and glycidamide hemoglobin adducts 
Blood samples were sent to the Center for Disease Control and Prevention (CDC) Protein 
Biomarker Laboratory (Atlanta, USA) to measure HbAA and HbGA. Details of the methodology 
can be found elsewhere (7,26). Briefly, 300 µL of red blood cells were hemolyzed and analyzed 
using HPLC/tandem mass spectrometry (HPLC/MS/MS). Laboratory personnel were blinded to 
9 
 
the case-control status of participants, and blood samples were analyzed in a randomized 
manner. Concentrations of HbAA and HbGA were reported relative to the amount of 
hemoglobin (pmol per g of Hb), and two independent measures were performed for each 
sample. The lower limits of detection for this method are 3 pmol/g of Hb for HbAA, and 4 
pmol/g of Hb for HbGA. All of the HbAA and HbGA measurements were within the limits of 
detection. In the present study, 42 of the 751 blood samples were sent in duplicate to the 
laboratory to independently assess the reproducibility of the hemoglobin adduct measures, 
which had intraclass correlation coefficients of 0.94 for HbAA and 0.92 for HbGA. The percent 
coefficient of variation (CV) was estimated using log-transformed (log2) values, and was 9.9 for 
HbAA and 12.0 for HbGA. 
Statistical methods 
Unconditional logistic regression models were used to estimate odds ratios (OR) and 95% 
confidence intervals (CI) for the association between biomarkers levels of acrylamide and 
glycidamide and the risk of EOC. Conditional logistic regression model were also evaluated in a 
sensitivity analyses.  
All statistical models were adjusted for matching factors [age at recruitment (in years), 
country, time of the day of blood draw, date of blood draw, and fasting status] and covariates 
including OC use (never, ever, unknown), HRT use (never, ever, unknown), alcohol 
consumption (non-drinkers, drinkers of 0-6, >6-12, >12-24, and >24 g/day), parity (nulliparous, 
1, 2, ≥3, parous but with missing number of full-term pregnancies), age at menopause (years), 
age at first menstrual period (years), and BMI (kg/m2). Lifestyle, anthropometric, and 
reproductive variables such as physical activity using the Cambridge index(27), education level 
(none, primary, technical/professional, secondary, and higher education), height (cm) ,weight 
(kg), hip circumference (cm), waist circumference (cm), duration of using OC (years), duration 
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of using HRT (years), and age at first birth (years) were evaluated as potential confounders, but 
were not included in final models because they did not change effect estimates >10%.  
Restricted cubic splines with 3, 4, and 5 knots were evaluated, and indicated non-monotonic 
relations between each of the four biomarker variables and EOC risk. Since the relations were 
not linear, even when exposure variables were logarithmically (log2) transformed, results for 
continuous biomarker variables were not presented (28). For each biomarker quintile, the 
median was estimated, and was included in a score test to evaluate dose-response trends. The 
four continuous biomarker variables HbAA, HbGA, sum of total adducts (HbAA+HbGA) and 
HbGA/HbAA ratio were categorized into quintiles based on the exposure distribution in 
controls. Biomarker quartiles were evaluated in stratified analyses.  
Analyses were also carried out excluding borderline tumors (n=2), and by histologic subtypes: 
invasive serous EOC, invasive serous EOC combined with NOS, and non-serous EOC (which 
included endometrioid, mucinous, clear cell, and NOS tumors).  
Effect measure modification was evaluated by BMI (<25 vs ≥25 kg/m2), HRT (never vs ever 
users), OC (never vs ever users), and alcohol intake (never vs ever drinkers) using a likelihood 
ratio test (LRT). These variables were selected since they are established risk or preventive 
factors, or because they may affect the activity of Cyp2e1 (29). All statistical tests were two-
sided and evaluated at α-level 0.05. All analyses were performed using SAS v. 9.1 (Cary, North 
Carolina, USA). 
Results 
Description of the study population  
The present nested case–control study was based on 334 incident EOC cases (of which 191 
were classified as serous), and 417 controls. A large proportion of cases and controls were 
from the UK and The Netherlands (table 1). Among cases, the median (quartile range) of HbAA 
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and HbGA levels were 42.2 (33.9-54.4) and 37.0 (28.5-49.5), respectively; whereas controls had 
HbAA and HbGA levels of 43.1 (33.8-54.8) and 35.4 (26.0-49.9), respectively (table 1). Cases 
were slightly younger than controls (58.4 vs 59.2 years), tended to have higher BMI values 
(26.4 vs 25.8 kg/m2), a higher proportion of HRT users (27.8% vs 18.9%), and were less likely to 
take OC (35.6% vs 41.7%). There were no major differences between cases and controls 
regarding age at menopause, age at first menstrual period, and parity (table 1). The median 
interval between the date of blood draw and the date at diagnosis for cases was 6.2 years. 
Overall EOC and serous EOC risk 
Four multivariate unconditional logistic regression analyses were performed for the 
association between each biomarker exposure variable and EOC risk. No associations were 
observed between HbAA levels analyzed in quintiles and EOC risk. Participants with HbGA 
levels >52.71 pmol/g of Hb (fifth quintile) were at non-significant increased EOC risk (ORQ5vsQ1: 
1.63, 95%CI: 0.92-2.86). The sum of total adducts was also analyzed. Compared to women with 
≤56.70 pmol/g of Hb (reference group), the ORs for the fourth and fifth quintiles were elevated 
but none were statistically significant. Participants classified in the second and third quintile of 
HbAA+HbGA were at higher risk of developing EOC (ORQ2vsQ1: 1.81, 95%CI: 1.06-3.10, and 
(ORQ3vsQ1: 2.00, 95%CI: 1.16-3.45). 
Similar models were also evaluated for invasive serous EOC. Despite not observing any 
statistically significant associations between biomarker levels (HbAA, HbGA, HbAA+HbGA, and 
HbGA/HbAA) and serous EOC risk, positive non-statistically significant associations were 
observed for upper vs. lower quintiles of HbGA and HbAA+HbGA (table 2). Similar patterns 
were found when borderline tumors were excluded, when non-serous tumors were evaluated, 
and when invasive serous and NOS were combined in the same analyses (data not shown).  
Sensitivity analyses were conducted using conditional logistic regression models, which 
included 261 cases and 416 controls, to estimate ORs of EOC for each biomarker level. Overall, 
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no statistically significant association were observed; nonetheless, results showed similar 
patters compared to the ones obtained using unconditional logistic regression models (table 
2). 
Effect measure modification in EOC  
Although some individual ORs were statistically significant, no consistent evidence for effect 
measure modification by BMI, alcohol intake, OC use (all LRT p-values >0.07; Table 3), or by 
HRT use (data not shown) was observed. 
Discussion 
The present nested case-control study was performed to assess the association between 
circulating hemoglobin adducts of acrylamide and glycidamide exposure and the risk of EOC in 
non-smoking postmenopausal women from the EPIC cohort. Overall our results do not support 
the hypothesis of an association between acrylamide or glycidamide biomarker levels and EOC 
risk; although increased risks were observed for some middle quintiles of HbGA and 
HbAA+HbGA, and non-statistically significant increased risk for serous EOC was observed for 
the fifth vs the first quintile of HbGA and HbAA+HbGA. No evidence for effect measure 
modification was noted when subgroups were analyzed.  
Acrylamide is thought be carcinogenic through its reactive epoxide, glycidamide, which forms 
DNA adducts and induces tumor development in animal models (30). Epidemiological evidence 
for an association between dietary acrylamide consumption and EOC risk is controversial. Only 
two of the five published studies (four prospective studies and one case-control study) found 
positive associations or suggestive increased risks for the relation between acrylamide 
(measured using FFQs) and overall EOC or serous EOC (16,18). The main results of the present 
nested case-control study are in line with the results presented in the Italian case-control, the 
SMC, and the EPIC cohort study (17,19,20).  
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A previous nested case-control biomarker study (conducted within the NHS and the NHSII), 
also concluded that there were no associations between adduct levels (measured as HbAA, 
HbGA, and HbAA+HbGA) and EOC or serous EOC risk (21). However, most of the effect 
estimates presented in the NHS/NHSII study were below the null value; unlike those observed 
in the current EPIC study. Moreover, the NHS/NHSII study included participants who were pre- 
peri-menopausal, and current or former smokers; whereas the present study was based on 
postmenopausal non-smoking women, since our aim was to evaluate the effect of dietary 
acrylamide exposure, and tobacco smoking is widely recognized to influence hemoglobin 
adduct concentrations (7,31).  
Blood samples from both EPIC and the NHS/NHSII studies were measured in the same 
laboratory using the same protocol. Among cases, the median adducts levels presented in the 
NHS/NHSII study were 63.8, 49.5, and 112.6 pmol/g Hb, whereas in the present study median 
adducts levels were lower at 42.2, 37.0, and 79.3 pmol/g Hb for HbAA, HbGA, and 
HbAA+HbGA, respectively. To avoid possible confounding by tobacco smoking, the NHS/NHSII 
study restricted the analyses to non-smoking women at the time of blood extraction (230 
cases vs 460 controls), and categorized exposures in tertiles based on the distribution in non-
smoking controls; however, referent group cutpoints were higher for HbAA, HbGA and 
HbAA+HbGA (0-52.3, 0-40.2, and 0-95.7 pmol/g Hb, respectively) compared to those 
presented in the current study (≤36.5, ≤29.6, and ≤66.2 pmol/g Hb, respectively) (tertile data 
not shown in tables). The minimum detectable ORQ5 at 80% power in our study was 1.65, 
which is similar to the minimum detectable OR (1.78) reported by the NHS/NHSII study.  
The design of the present nested-case control study is one of the major strengths, as we 
wanted to evaluate the dietary contribution to acrylamide biomarker levels and EOC risk, and 
avoid confounding from tobacco smoking and hormonal oscillations. Dietary acrylamide 
exposure assessment using FFQs has been criticized due to its low correlation with hemoglobin 
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adducts of exposure in many epidemiological studies (correlation range: 0.08 to 0.43) (19); 
however, this weakness was avoided since our exposure data were based on hemoglobin 
adducts levels. Further, HbAA and HbGA levels were measured in blood collected before 
cancer diagnosis, and following exhaustive quality assurance and quality control laboratory 
protocols (7,26). There are some limitations that should be noted: (a) only one blood sample 
was collected at baseline from each participant, and this did not allow us to estimate intra-
individual variation; however, a prior study conducted in 45 women from the NHS-II (who 
provided 2-3 blood samples over a period of 1-3 years) suggested that biomarkers of 
acrylamide intake were reproducible over time (32) (b) although the EPIC study has 
prospective information for most of the known EOC risks factors, information on 
endometriosis and polycystic ovary syndrome could not be accounted for in our statistical 
analyses since it was not collected, (c) occupational exposure and environmental tobacco 
smoke exposure could not be evaluated due to the large number of missing values (>50%) for 
environmental tobacco smoke, and the low prevalence of occupational exposure information 
in women, (d) and despite having a larger number of EOC cases (n=334) than the NHS/NHSII 
study (n=263), we were unable to perform analyses for EOC subtypes other than serous due to 
small sample size.  
In summary, this nested case-control study within the EPIC cohort failed to observe a clear 
association between biomarkers of acrylamide exposure (measured as hemoglobin adducts of 
acrylamide and glycidamide in red blood cells) and the risk of EOC or serous EOC. Additional 
studies with larger sample size, and pooled analysis of existing studies should be performed to 
exclude any possible association.   
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Table 1. Description of the study population from a nested case-control study of acrylamide biomarkers and EOC in the EPIC cohort 
 
All EOC cases 
n=334 
Invasive serous EOC cases 
n=191 
Controls 
n=417 
HbAA pmol/g of Hb a 42.2 (33.9-54.4) 42.2 (33.8-56.6) 43.1 (33.8-54.8) 
HbGA pmol/g of Hb a 37.0 (28.5-49.5) 37.0 (28.1-52.2) 35.4 (26.0-49.9) 
HbAA+HbGA pmol/g of Hb a 79.3 (62.5-105.4) 82.1 (62.0-107.8) 78.7 (60.6-106.0) 
HbGA/HbAA pmol/g of Hb a 0.9 (0.7-1.0) 0.9 (0.7-1.0) 0.8 (0.7-1.0) 
Age at recruitment (y) a 58.4 (53.8-63.4) 57.7 (53.0-62.7) 59.2 (54.4-64.2) 
Age at first menstrual period (y) a 13.0 (12.0-14.0) 13.0 (12.0-14.0) 13.0 (12.0-14.0) 
Age at menopause (y) a 49.5 (49.0-52.0) 49.5 (49.0-51.0) 49.5 (48.0-52.0) 
BMI (Kg/m2) a 26.4 (23.4-29.3) 26.0 (22.8-29.3) 25.8 (23.2-29.5) 
Country b    
France 32(9.6) 23 (12.0) 30 (7.2) 
Italy 43 (12.9) 25 (13.1) 52 (12.5) 
Spain 36 (10.8) 21 (11.0) 55 (13.2) 
United Kingdom 71 (21.3) 29 (15.2) 94 (22.5) 
The Netherlands 59 (17.7) 37 (19.4) 78 (18.7) 
Greece 27 (8.1) 10 (5.2) 43 (10.3) 
Germany 45(13.5) 33 (17.3) 46 (11.0) 
Sweden 21 (6.3) 13 (6.8) 19 (4.6) 
Fasting status b  
 
 
Unknown 3 (0.9) 1 (0.5) 2 (0.5) 
<3 hours 169 (50.6) 97 (50.8) 213 (51.1) 
3-6 hours 44 (13.2) 23 (12.0) 58 (13.9) 
>6 hours 118 (35.3) 70 (36.7) 44 (34.5) 
Alcohol consumption b    
Non drinker 80 (24.0) 47 (24.6) 93 (22.3) 
>0-6 166 (49.7) 95 (49.7) 178 (42.7) 
>6-12 35 (10.5) 22 (11.5) 73 (17.5) 
>12-24 38 (11.4) 19 (10.0) 50 (12.0) 
>24-60 15 (4.5) 8 (4.2) 23 (5.5) 
Ever use of OC b    
Unknown 6 (1.8) 3 (1.6) 4 (1.0) 
No 209 (62.6) 114 (59.7) 239 (57.3) 
Yes 119 (35.6) 74 (38.7) 174 (41.7) 
Ever use of HRTb    
Unknown 12 (3.6) 8 (4.2) 13 (3.1) 
No 229 (68.6) 123 (64.4) 325 (77.9) 
Yes 93 (27.8) 60 (31.4) 79 (18.9) 
Parity b    
Unknown 41 (12.3) 27 (14.1) 58 (13.9) 
1 child 129 (38.6) 81 (42.4) 161 (38.6) 
2 children 99 (29.6) 53 (27.8) 141 (33.8) 
>=3 children 48 (14.4) 23 (12.0) 44 (10.6) 
Nulliparous 8 (2.4) 4 (2.1) 9 (2.2) 
Parous but with missing number of full-term pregnancies 9 (2.7) 3 (1.6) 4 (1.0) 
EOC, epithelial ovarian; EPIC, European Prospective Investigation into Cancer and Nutrition; HbAA, hemoglobin adducts of acrylamide; 
HbGA, hemoglobin adducts of glycidamide, BMI, body mass index; OC, oral contraceptive; HRT, hormone replacement therapy 
a Median and quartile range (25th – 75th percentile) 
b number (n) and percent (%) 
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Table 2. OR and 95% CI for biomarkers of acrylamide exposure and EOC risk in a nested case-control study in the EPIC cohort 
Overall EOC a 
Sensitivity analysis b 
Invasive serous EOC a 
Overall EOC 
Exposure cut-points 
Cases Controls 
OR (95%CI) 
P-
trend  
Cases Controls 
OR (95%CI) 
P-
trend  
Cases Controls 
OR (95%CI) 
P-
trend  n=334 n=417 n=261 n=416 n=191 N=417 
H
b
A
A
 
≤31.30 60 82 1.00 (ref) 
0.86 
45 81 1.00 (ref) 
0.94 
32 82 1.00 (ref) 
0.59 
31.31-39.10 80 85 1.25( 0.75- 2.10) 60 85 1.25( 0.71- 2.20) 47 85 1.29( 0.68- 2.45) 
39.11-47.20 60 81 1.01( 0.58- 1.76) 48 81 1.11( 0.61- 2.01) 34 81 0.96( 0.48- 1.92) 
47.21-59.20 71 86 1.20( 0.69- 2.06) 58 86 1.12( 0.63- 2.00) 36 86 1.27( 0.65- 2.48) 
>59.21 63 83 1.19( 0.67- 2.11) 50 83 1.04( 0.56- 1.93) 42 83 1.55( 0.78- 3.09) 
H
b
G
A
 
≤24.70 51 83 1.00 (ref) 
0.04 
39 82 1.00 (ref) 
0.06 
29 83 1.00 (ref) 
0.20 
24.71-31.30 62 83 1.23( 0.72- 2.11) 46 83 1.05( 0.60- 1.85) 36 83 1.37( 0.70- 2.67) 
31.31-41.20 91 84 2.14( 1.27- 3.60) 75 84 1.76( 1.01- 3.08) 49 84 2.11( 1.10- 4.03) 
41.22-52.70 58 84 1.32( 0.75- 2.33) 43 84 0.81( 0.43- 1.50) 32 84 1.57( 0.78- 3.18) 
>52.71 72 83 1.63( 0.92- 2.86) 58 83 1.22( 0.66- 2.26) 45 83 1.91( 0.96- 3.81) 
Su
m
 o
f 
H
b
A
A
 +
 
H
b
G
A
 
≤56.70 48 83 1.00 (ref) 
0.14 
38 82 1.00 (ref) 
0.28 
28 83 1.00 (ref) 
0.30 
56.71-71.00 77 83 1.81( 1.06- 3.10) 54 83 1.41( 0.79- 2.52) 43 83 1.67( 0.86- 3.26) 
71.01-88.90 80 84 2.00( 1.16- 3.45) 68 84 1.77( 0.98- 3.19) 45 84 2.07( 1.06- 4.06) 
88.91-112.60 64 84 1.75( 0.98- 3.13) 49 84 1.09( 0.58- 2.02) 33 84 1.68( 0.82- 3.44) 
>112.61 65 83 1.60( 0.89- 2.87) 52 83 1.22( 0.65- 2.29) 42 83 1.90( 0.94- 3.83) 
R
at
io
 o
f 
H
b
G
A
/H
b
A
A
 ≤0.70 55 83 1.00 (ref) 
0.46 
41 83 1.00 (ref) 
0.66 
33 83 1.00 (ref) 
0.71 
0.71-0.79 55 81 1.07( 0.62- 1.83) 42 81 0.96( 0.53- 1.74) 33 81 1.18( 0.61- 2.30) 
0.80-0.90 78 89 1.43( 0.85- 2.41) 61 89 1.22( 0.71- 2.10) 43 89 1.43( 0.75- 2.74) 
0.91-0.99 69 79 1.53( 0.87- 2.67) 59 78 1.37( 0.77- 2.45) 40 79 1.59( 0.80- 3.16) 
>1.00 77 85 1.40( 0.82- 2.39) 58 85 1.01( 0.56- 1.81) 42 85 1.42( 0.74- 2.74) 
OR, odds ratio; CI, confidence intervals; EOC, epithelial ovarian cancer; EPIC, European Prospective Investigation into Cancer and Nutrition; HbAA, hemoglobin adducts of acrylamide; HbGA, hemoglobin adducts of 
glycidamide. 
a Models are adjusted for age at recruitment, country, fasting status, date at blood collection, time of the day of blood collection, OC use, HRT use, alcohol intake, parity, age at menopause, age at first menstrual period, and 
BMI. 
b Conditional logistic regression model adjusting for matching factors and OC use, HRT use, alcohol intake, parity, age at menopause, age at first menstrual period, and BMI. 
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Table 3. Stratified analyses: OR and 95% CI for biomarkers of acrylamide exposure and EOC risk in an EPIC nested case-control study in the EPIC cohort 
  
  Normal and Underweight Overweight and Obese Never drinkers Drinkers Non-Oral contraceptive users Oral contraceptive users 
Cutpoints Cases Controls OR (95%CI)a Cases Controls OR (95%CI)a Cases Controls OR (95%CI)b Cases Controls OR (95%CI)b Cases Controls 
OR 
(95%CI)c 
Cases Controls OR (95%CI)c 
H
b
A
A
 
≤33.60 35 37 1.00 (ref) 45 67 1.00 (ref) 19 26 1.00 (ref) 61 78 1.00 (ref) 55 74 1.00 (ref) 24 30 1.00 (ref) 
33.61-
42.70 
35 42 
1.01( 0.44- 
2.33) 
55 61 
1.15( 0.63- 
2.09) 
27 21 
1.35( 0.51- 
3.52) 
63 82 
1.11( 0.65- 
1.92) 
55 45 
1.47( 0.81- 
2.68) 
32 55 
0.80( 0.34- 
1.89) 
42.71-
54.60 
28 50 
0.68( 0.29- 
1.59) 
56 55 
1.52( 0.81- 
2.87) 
19 28 
0.65( 0.22- 
1.96) 
65 77 
1.40( 0.80- 
2.43) 
55 58 
1.22( 0.66- 
2.26) 
27 46 
1.12( 0.44- 
2.88) 
>54.61 39 46 
1.23( 0.54- 
2.84) 
41 59 
0.93( 0.47- 
1.82) 
15 18 
0.77( 0.24- 
2.52) 
65 87 
1.19( 0.67- 
2.12) 
44 62 
0.85( 0.44- 
1.66) 
36 43 
1.60( 0.64- 
4.00) 
LRT 0.07 0.42 0.18 
H
b
G
A
 
≤25.90 35 49 1.00 (ref) 27 54 1.00 (ref) 11 22 1.00 (ref) 51 81 1.00 (ref) 44 62 1.00 (ref) 16 41 1.00 (ref) 
26.91-
35.20 
38 46 
1.66( 0.76- 
3.60) 
51 59 
1.45( 0.76- 
2.78) 
16 19 
1.85( 0.53- 
6.53) 
73 86 
1.47( 0.87- 
2.49) 
50 57 
1.22( 0.67- 
2.24) 
37 47 
2.91( 1.18- 
7.14) 
35.21-
49.90 
29 42 
1.53( 0.67- 
3.51) 
72 63 
2.10( 1.08- 
4.08) 
35 26 
4.32( 1.32- 
14.18) 
66 79 
1.80( 1.04- 
3.13) 
67 57 
2.02( 1.09- 
3.76) 
32 47 
2.33( 0.90- 
5.99) 
>49.91 35 38 
1.82( 0.79- 
4.22) 
47 66 
1.29( 0.64- 
2.63) 
18 26 
1.39( 0.38- 
5.03) 
64 78 
1.62( 0.91- 
2.89) 
48 63 
1.11( 0.57- 
2.15) 
34 39 
3.33( 1.27- 
8.77) 
LRT 0.60 0.66 0.33 
Su
m
 o
f 
H
b
A
A
 +
 H
b
G
A
 ≤59.80 34 41 1.00 (ref) 34 62 1.00 (ref) 11 21 1.00 (ref) 57 82 1.00 (ref) 47 71 1.00 (ref) 19 32 1.00 (ref) 
59.81-
78.70 
34 48 
1.12( 0.50- 
2.49) 
62 58 
1.85( 1.00- 
3.43) 
28 22 
2.80( 0.91- 
8.59) 
68 84 
1.30( 0.77- 
2.22) 
57 51 
1.60( 0.88- 
2.92) 
37 54 
1.59( 0.67- 
3.80) 
78.80-
106.00 
34 45 
1.27( 0.55- 
2.93) 
54 59 
1.51( 0.79- 
2.88) 
26 28 
1.97( 0.59- 
6.54) 
62 76 
1.52( 0.87- 
2.63) 
56 51 
1.72( 0.93- 
3.20) 
30 51 
1.21( 0.48- 
3.06) 
>106.01 35 41 
1.48( 0.63- 
3.50) 
47 63 
1.23( 0.63- 
2.43) 
15 22 
1.01( 0.27- 
3.85) 
67 82 
1.46( 0.83- 
2.58) 
49 66 
1.06( 0.55- 
2.07) 
33 37 
2.14( 0.83- 
5.53) 
LRT 0.34 0.40 0.29 
R
at
io
 o
f 
H
b
G
A
/H
b
A
A
 ≤0.70 39 66 1.00 (ref) 28 37 1.00 (ref) 3 15 1.00 (ref) 64 88 1.00 (ref) 39 49 1.00 (ref) 26 54 1.00 (ref) 
0.71-0.80 39 48 
1.99( 0.96- 
4.15) 
37 55 
0.88( 0.43- 
1.78) 
21 21 
15.55( 1.74-
138.79) 
55 82 
1.02( 0.61- 
1.72) 
46 59 
1.02( 0.54- 
1.91) 
30 44 
2.10( 0.90- 
4.87) 
0.81-1.00 39 31 
3.06( 1.34- 
7.01) 
65 77 
1.22( 0.62- 
2.39) 
29 24 
17.90( 2.00-
160.05) 
75 84 
1.48( 0.88- 
2.50) 
69 65 
1.79( 0.96- 
3.32) 
31 41 
2.21( 0.90- 
5.45) 
>1.01 20 30 
1.06( 0.44- 
2.52) 
67 73 
1.15( 0.59- 
2.23) 
27 33 
11.20( 1.27- 
99.05) 
60 70 
1.24( 0.73- 
2.11) 
55 66 
1.17( 0.63- 
2.19) 
32 35 
1.86( 0.77- 
4.51) 
LRT 0.18 0.09 0.61 
EOC, epithelial ovarian cancer; EPIC, European Prospective Investigation into Cancer and Nutrition; HbAA, hemoglobin adducts of acrylamide; HbGA, hemoglobin adducts of glycidamide. 
a Adjusted for country, fasting status, date at blood collection, time of the day of blood collection, OC use, HRT use, alcohol intake, parity, age at menopause, and age at first menstrual period. 
b Adjusted for country, fasting status, date at blood collection, time of the day of blood collection, OC use, HRT use, parity, age at menopause, age at first menstrual period, and BMI. 
c Adjusted for country, fasting status, date at blood collection, time of the day of blood collection, HRT use, alcohol intake, parity, age at menopause, age at first menstrual period, and BMI. 
d All LRT P-values for effect measure modification are based on the categorical exposure adduct variable. 
 
